



Verein zur Förderung
Medizinisch-Wissenschaftlicher
Forschung

SYMPOSIUM

Herausforderung in der Herzchirurgie: Mitralklappenchirurgie 2024



PROGRAMM

22.–23. November 2024
Convention Center – Schloss Luberegg
Emmersdorf an der Donau

PROGRAMM

Freitag 22. November 2024

13:50 – 14:00 **Begrüßung**
D. Wiedemann, W. Dietl, St. Pölten

Session 1 **Basics**
Vorsitz: W. Dietl, St. Pölten

14:00 – 14:20 **Anatomie und Physiologie der Mitralklappe**
U. Neuhold, Krems

14:20 – 14:50 **Pathophysiologie der Mitralklappe**
D. Haas, Wr. Neustadt

14:50 – 15:10 **Interoperative Diagnostik der Mitralklappe**
G. Valicek, St. Pölten

15:10 – 15:25 **Paneldiskussion**

15:25 – 16:00 **Kaffeepause**
Besuch der Industrieausstellung und Workshops

16:00 – 16:45 **HANDS-ON WORKSHOP I**
MITRIS RESILIA mitral valve (max. 10 TN)



Session 2 **State of the Art**
Vorsitz: D. Wiedemann, St. Pölten

16:00 – 16:45 **Keynote lecture 1:**
Contemporary surgical therapy of the mitral valve
A. Weymann, Hannover

16:45 – 17:30 **Keynote lecture 2:**
Contemporary interventional therapy: Beyond Mitraclip
P. Vock, St. Pölten

19:00 **Gemeinsames Abendessen**

PROGRAMM

Samstag 23. November 2024

Session 3	Kontroversen in der chirurgischen Therapie der Mitralklappe Vorsitz: B. Podesser, St. Pölten
09:00 – 09:30	Minimal Invasive Mitralklappen Chirurgie: P. Bergmann, St. Pölten: Pro A. Kocher, Wien: Con
09:30 – 10:00	Mitralklappen Ersatz: D. Wiedemann, St. Pölten: Pro Biological G. Laufer, Graz: Pro Mechanical
10:00 – 10:30	Kaffeepause Besuch der Industrierausstellung und Workshops
10:30 – 11:15	HANDS-ON WORKSHOP II MITRIS RESILIA mitral valve (max. 10 TN)
	 Edwards
Session 4	Hot Topics in Mitral Valve Surgery Vorsitz: A. Kocher, Wien
10:30 – 11:00	Timing der Operation bei Endokarditis: Early: W. Dietl, St. Pölten Late: B. Podesser, St. Pölten
11:00 – 11:15	Antikoagulation nach MK-Operationen L. Resemann, F. Kainz, St. Pölten
11:15 – 11:30	ONX – Wissenschaft und Praxis A. Kocher, Wien
11:30 – 12:00	Rhythmuschirurgie in Rahmen von Mitralklappen-Operationen E. Osorio, Wien
12:00 – 12:30	Verabschiedung W. Dietl, D. Wiedemann, St. Pölten

WORKSHOPS

Edwards: Mitris Resilia mitral valve

Getinge: Endovene

ALLGEMEINE INFORMATION

Herausforderungen in der Herzchirurgie:

Mitralklappenchirurgie 2024

22.–23. November 2024, Convention Center – Schloss Luberegg

Veranstalter:

Karl Landsteiner Gesellschaft
Institut für innovative Herzchirurgie



Verein zur Förderung
Medizinisch-Wissenschaftlicher
Forschung

Wissenschaftliche Leitung:

Prim. Assoc. Prof. Univ.-Doz. Dr. Dominik Wiedemann
OA Dr. Wolfgang Dietl

Tagungsort:

Convention Center – Schloss Luberegg
Luberegg 18
3644 Emmersdorf

Organisation – Fachausstellung – Sponsoring:



Medizinische Ausstellungs- und Werbegesellschaft
Freyung 6/3, 1010 Wien
Frau Nicole Lehner, Tel.: +43 1 536 63 -20
E-Mail: kardio@maw.co.at
Website: www.maw.co.at

Online Anmeldung:

<https://registration.maw.co.at/herzchirurgie24>

DFP

Diese Veranstaltung wird für das Diplomfortbildungsprogramm
der ÖÄK eingereicht

SPONSOREN

Hauptsponsor



Edwards

Sponsoren



AtriCure

B | BRAUN

GETINGE 

Medtronic



POSTHORAX®



BÖCK 
medizintechnik

CytoSorbents™



MIN | MEDICAL

 **TERUMO**
Aortic

XENIOS | A FRESENIUS
MEDICAL CARE
COMPANY



Broad spectrum of treatment options in both, heart and lung support

- Treatments for heart and lung support on one platform
- For ECMO treatments with „Advanced Mode“ applicable for neonates up to adults
- From partial CO₂ removal to adequate oxygenation^[1,2]
- VV & VA ECMO applications
 - ✓ ICU
 - ✓ Operating room
 - ✓ Cardiac catheterization lab

This information is provided exclusively to healthcare professionals located within the EU. The spectrum described is only cleared and available in selected EU countries. For further information please contact sales@xenios-ag.com

1 Redwan B. et al., (2015) Intraoperative veno-venous extracorporeal lung support in thoracic surgery: a single-centre experience.

Interact Cardiovasc Thorac Surg: ivv253 [141]

2 Braune S. et al., (2016) The feasibility and safety of extracorporeal carbon dioxide removal to avoid intubation in patients with COPD unresponsive to non-invasive ventilation for acute hypercapnic respiratory failure (ECLAIR study): multicentre case-control study. Intensive Care Med 42(9): 1437- 1444 [117]

End of 2016, Xenios became a part of Fresenius Medical Care, the world's leading provider of products and services for people with chronic kidney failure.

XENIOS AG • Im Zukunftspark 1 • 74076 Heilbronn • Germany • Phone +49 (0) 7131 2706 0 • www.xenios-ag.com

RESILIA^{*} tissue^{*}

Tissue with a difference



INSPIRIS RESILIA
aortic valve



MITRIS RESILIA
mitral valve



Learn more at
edwards.com/gb/resilia

* No clinical data are available that evaluate the long-term impact of RESILIA tissue in patients. Additional clinical data for up to 10 years of follow-up are being collected to monitor the long-term safety and performance of RESILIA tissue.

Medical device for professional use. For a listing of indications, contraindications, precautions, warnings, and potential adverse events, please refer to the Instructions for Use (consult eifu.edwards.com where applicable).

Edwards, Edwards Lifesciences, the stylized E logo, INSPIRIS, INSPIRIS RESILIA, MITRIS, MITRIS RESILIA and RESILIA are trademarks of Edwards Lifesciences Corporation or its affiliates. All other trademarks are the property of their respective owners.


© 2024 Edwards Lifesciences Corporation. All rights reserved. PP--EU-8595 v1.0

Edwards Lifesciences Sàrl • Route de l'Etraz 70, 1260 Nyon, Switzerland • edwards.com



Edwards

Medtronic



Avalus Ultra™
bioprosthesis

Fit for the
future
right from
the start.

A man in a red long-sleeved shirt and khaki shorts stands with his back to the camera, arms raised in a 'V' shape, on a wooden pier overlooking a body of water at sunset. The word 'future' is written in large white letters, with the letter 'u' highlighted in a teal color that matches the circular graphic in the top right.

With every beat,
expect more.

The material shown should not be considered the exclusive source of information, it does not replace or supersede information contained in the device manual(s). Please note that the intended use of a product may vary depending on geographical approvals. See the device manual(s) for detailed information regarding the intended use, the implant procedure, indications, contraindications, warnings, precautions, and potential adverse events. For a MRI compatible device(s), consult the MRI information in the device manual(s) before performing a MRI. If a device is eligible for eIFU usage, instructions for use can be found at Medtronic's website manuals.medtronic.com. Manuals can be viewed using a current version of any major internet browser. For best results, use Adobe Acrobat® Reader with the browser. Medtronic products placed on European markets bear the CE mark and the UKCA mark (if applicable). For any further information, contact your local Medtronic representative.

13473220-en-gb-emea ©2024 Medtronic. Medtronic, Medtronic logo, and Engineering the extraordinary are trademarks of Medtronic. All other brands are trademarks of a Medtronic company.